4.7 Article

Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia

期刊

BLOOD
卷 112, 期 10, 页码 4178-4183

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-06-165027

关键词

-

资金

  1. National Cancer Institute (NCI) [SPEC U01 CA114762]
  2. Penelope London Foundation
  3. Friedman Fund for Childhood Leukemia
  4. Walter Family Pediatric Leukemia Fund
  5. Pediatric Cancer Foundation [CA093552-02, NCI CA 51 001, CA 78 224, CA21765]
  6. National Institutes of Health (NIH)/National Institute of General Medical Sciences Pharmacogenetics Research Network and Database [U01 GM61393, U01GM61374]
  7. NIH
  8. American Lebanese Syrian Associated Charities
  9. CureSearch

向作者/读者索取更多资源

The underlying pathways that lead to relapse in childhood acute lymphoblastic leukemia (ALL) are unknown. To comprehensively characterize the molecular evolution of relapsed childhood B-precursor ALL, we used human 500K single-nucleotide polymorphism arrays to identify somatic copy number alterations (CNAs) in 20 diagnosis/relapse pairs relative to germ line. We identified 758 CNAs, 66.4% of which were less than 1 Mb, and deletions outnumbered amplifications by approximately 2.5:1. Although CNAs persisting from diagnosis to relapse were observed in all 20 cases, 17 patients exhibited differential CNA patterns from diagnosis to relapse. Of the 396 CNAs observed in 20 relapse samples, only 69 (17.4%) were novel ( absent in the matched diagnosis samples). EBF1 and IKZF1 deletions were particularly frequent in this relapsed ALL cohort (25.0% and 35.0%, respectively), suggesting their role in disease recurrence. In addition, we noted concordance in global gene expression and DNA copy number changes (P = 2.2 x 10(-16)). Finally,relapse-specific focal deletion of MSH6 and, consequently, reduced gene expression were found in 2 of 20 cases. In an independent cohort of children with ALL, reduced expression of MSH6 was associated with resistance to mercaptopurine and prednisone, thereby providing a plausible mechanism by which this acquired deletion contributes to drug resistance at relapse. (Blood. 2008; 112: 4178-4183)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Vaccines against SARS-CoV-2 are safe to administer in patients with antibodies to pegaspargase

Hope D. Swanson, Hana Hakim, Diego R. Hijano, Ted Morton, Shane Cross, Hiroto Inaba, Sima Jeha, Ching-Hon Pui, Seth E. Karol

Summary: This study aimed to evaluate the safety of SARS-CoV-2 vaccines in patients with anti-pegaspargase antibodies. The results showed that these patients tolerated the vaccines well, which also use polyethylene glycol as a stabilizing agent, with no significant adverse reactions observed.

CANCER MEDICINE (2023)

Article Oncology

Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study

Andishe Attarbaschi, Anja Moericke, Christine J. Harrison, Georg Mann, Andre Baruchel, Barbara De Moerloose, Valentino Conter, Meenakshi Devidas, Sarah Elitzur, Gabriele Escherich, Stephen P. Hunger, Keizo Horibe, Atsushi Manabe, Mignon L. Loh, Rob Pieters, Kjeld Schmiegelow, Lewis B. Silverman, Jan Stary, Ajay Vora, Ching-Hon Pui, Martin Schrappe, Martin Zimmermann

Summary: This study aimed to investigate the prognostic factors and efficacy of allogeneic hematopoietic stem-cell transplantation (allo-HSCT) in the first remission of patients with noninfant childhood acute lymphoblastic leukemia (ALL) with 11q23/KMT2A rearrangements. The results showed that the prognosis of patients with noninfant 11q23/KMT2A-rearranged ALL has improved compared to historical data, but allo-HSCT did not improve outcomes. Targeted therapies are needed to reduce relapse and treatment-related mortality rates.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Letter Oncology

Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group

Kentaro Ohki, Ellie R. Butler, Nobutaka Kiyokawa, Shinsuke Hirabayashi, Anke K. Bergmann, Anja Moericke, Judith M. Boer, Helene Cave, Giovanni Cazzaniga, Allen Eng Juh Yeoh, Masashi Sanada, Toshihiko Imamura, Hiroto Inaba, Charles G. Mullighan, Mignon L. Loh, Ulrika Noren-Nystrom, Lee-Yung Shih, Marketa Zaliova, Ching-Hon Pui, Oskar A. Haas, Christine J. Harrison, Anthony V. Moorman, Atsushi Manabe

LEUKEMIA (2023)

Article Oncology

Association between body mass index at diagnosis and outcomes in Chinese children with newly diagnosed acute lymphoblastic leukemia

Wenting Hu, Yin Ting Cheung, Yanjing Tang, Li Hong, Yuan Zhu, Jing Chen, Zhuo Wang, Min Zhou, Yijin Gao, Jing Chen, Benshang Li, Huiliang Xue, Longjun Gu, Shuhong Shen, Jingyan Tang, Ching-Hon Pui, Hiroto Inaba, Jiaoyang Cai

Summary: Studies on the association between BMI at diagnosis and treatment outcomes in Chinese children with ALL have shown inconsistent results. While weight status was not associated with event-free survival or overall survival, overweight patients were at a higher risk of treatment-related mortality.

CANCER MEDICINE (2023)

Article Medicine, Research & Experimental

DNA methylation of the TPMT gene and azathioprine pharmacokinetics in children with very early onset inflammatory bowel disease

Davide Selvestrel, Gabriele Stocco, Marina Aloi, Serena Arrigo, Sabrina Cardile, Erika Cecchin, Mauro Congia, Debora Curci, Simona Gatti, Francesco Graziano, Carl D. Langefeld, Marianna Lucafo, Stefano Martelossi, Massimo Martinelli, Sofia Pagarin, Luca Scarallo, Elisabetta Francesca Stacul, Caterina Strisciuglio, Susan Thompson, Giovanna Zuin, Giuliana Decorti, Matteo Bramuzzo

Summary: This pharmacoepigenetic study aims to evaluate differences in DNA methylation and TPMT activity between patients with very early onset inflammatory bowel disease (VEO-IBD) and adolescents with IBD (aIBD). The study found that the DNA methylation level of cg22736354 in the TPMT gene neighborhood is lower in VEO-IBD patients, and it is associated with TPMT activity and azathioprine concentration.

BIOMEDICINE & PHARMACOTHERAPY (2023)

Article Hematology

Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis

David Spencer Mangum, Johnathon D. Bishop, Yinmei Zhou, Cheng Cheng, Seth E. Karol, Jeffrey E. Rubnitz, Raul C. Ribeiro, Jun J. Yang, Charles G. Mullighan, Sima Jeha, Ching-Hon Pui, Hiroto Inaba

Summary: Among children with acute lymphoblastic leukaemia, about 14.7% presented without peripheral blood blasts. While absence of blasts did not affect survival outcomes, these patients had distinct genetic and clinical characteristics, with a higher incidence of hyperdiploid B-ALL and lower rates of central nervous system involvement.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Biochemistry & Molecular Biology

Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response

Shawn H. R. Lee, Wenjian Yang, Yoshihiro Gocho, August John, Lauren Rowland, Brandon Smart, Hannah Williams, Dylan Maxwell, Jeremy Hunt, Wentao Yang, Kristine R. R. Crews, Kathryn G. G. Roberts, Sima Jeha, Cheng Cheng, Seth E. E. Karol, Mary V. V. Relling, Gary L. L. Rosner, Hiroto Inaba, Charles G. G. Mullighan, Ching-Hon Pui, William E. E. Evans, Jun J. J. Yang

Summary: Contemporary chemotherapy for childhood acute lymphoblastic leukemia is personalized based on clinical features, leukemia genomics, and minimal residual disease. However, the pharmacological basis of these prognostic variables is unclear. A study analyzing samples from 805 children with newly diagnosed leukemia identified variations in drug response and determined that certain subtypes were more sensitive to specific agents. The findings suggest opportunities for individualizing therapy and exploring alternative strategies for childhood acute lymphoblastic leukemia.

NATURE MEDICINE (2023)

Letter Hematology

Identification of TCF3 germline variants in pediatric B-cell acute lymphoblastic leukemia

Carolin Escherich, Wenan Chen, Satoshi Miyamoto, Yui Namikawa, Wenjian Yang, David T. Teachey, Zhenhua Li, Elizabeth A. Raetz, Eric Larsen, Meenakshi Devidas, Paul L. Martin, Gang Wu, Ching-Hon Pui, Stephen P. Hunger, Mignon L. Loh, Masatoshi Takagi, Jun J. Yang

BLOOD ADVANCES (2023)

Article Hematology

Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia

Zhenhua Li, Ti-Cheng Chang, Jacob J. Junco, Meenakshi Devidas, Yizhen Li, Wenjian Yang, Xin Huang, Dale J. Hedges, Zhongshan Cheng, Mary Shago, Andrew J. Carroll, Nyla A. Heerema, Julie Gastier-Foster, Brent L. Wood, Michael J. Borowitz, Lauren Sanclemente, Elizabeth A. Raetz, Stephen P. Hunger, Eleanor Feingold, Tracie C. Rosser, Stephanie L. Sherman, Mignon L. Loh, Charles G. Mullighan, Jiyang Yu, Gang Wu, Philip J. Lupo, Karen R. Rabin, Jun J. Yang

Summary: This study investigates the genomics of Down syndrome-related acute lymphoblastic leukemia (DS-ALL) and identifies 15 molecular subtypes, as well as abnormal activation of key genes. It also reveals the common occurrence of somatic genomic abnormalities mediated by gene rearrangements in DS-ALL and the association between subtype heterogeneity and prognosis. These findings provide important insights into the biology of DS-ALL and offer opportunities for individualized treatment.
Article Oncology

Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods

Georgios E. Christakopoulos, Kendra N. Walker, Jesse Smith, Clifford M. Takemoto, Yan Zheng, Ching-Hon Pui, Raul C. Ribeiro, Lei Wang, Stanley B. Pounds, Jeffrey E. Rubnitz, Hiroto Inaba

Summary: This study investigated the clinical management strategies and effects of cytoreduction in pediatric patients with acute myeloid leukemia (AML) and hyperleukocytosis. The results showed that LD-cytarabine treatment was safe and effective in reducing leukocyte counts in children with AML and hyperleukocytosis.

CANCER (2023)

Article Pharmacology & Pharmacy

Impact of Mercaptopurine Metabolites on Disease Outcome in the AIEOP-BFM ALL 2009 Protocol for Acute Lymphoblastic Leukemia

Raffaella Franca, Gabriele Stocco, Valentina Kiren, Antimo Tessitore, Franca Fagioli, Paola Quarello, Nicoletta Bertorello, Carmelo Rizzari, Antonella Colombini, Laura Rachele Bettini, Franco Locatelli, Luciana Vinti, Katia Girardi, Daniela Silvestri, Maria Grazia Valsecchi, Giuliana Decorti, Marco Rabusin

Summary: In the maintenance phase of the AIEOP-BFM ALL protocol, adjustments of mercaptopurine dosage are made based on the white blood cell count of patients. However, the concentration and variation of MP metabolites were found to have no direct impact on relapse, while children in the intermediate risk group had a higher risk of relapse. Understanding the mechanism behind the PACSIN2 rs2413739 genotype and its effect on outcomes requires further research.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Review Medicine, Research & Experimental

iPSCs as a groundbreaking tool for the study of adverse drug reactions: A new avenue for personalized therapy

Paola Rispoli, Tatiana Scandiuzzi Piovesan, Giuliana Decorti, Gabriele Stocco, Marianna Lucafo

Summary: Induced pluripotent stem cells (iPSCs) are a promising tool for studying drug toxicities and personalized medicine. They can be differentiated into any tissue of the human body, allowing for personalized pharmacological studies and investigation of physiological differentiation processes. iPSC-derived organoids provide a more accurate representation of native organs and are useful for studying adverse drug reactions.

WIRES MECHANISMS OF DISEASE (2023)

Article Hematology

Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report

Nathan P. Gossai, Meenakshi Devidas, Zhiguo Chen, Brent L. Wood, Patrick A. Zweidler-McKay, Karen R. Rabin, Mignon L. Loh, Elizabeth A. Raetz, Naomi J. Winick, Michael J. Burke, Andrew J. Carroll, Natia Esiashvili, Nyla A. Heerema, William L. Carroll, Stephen P. Hunger, Kimberly P. Dunsmore, Stuart S. Winter, David T. Teachey

Summary: The prognostic significance of CNS leukemic involvement in newly diagnosed T-ALL is not optimistic, and the outcomes are not affected by therapeutic differences or some treatment methods. Further research is needed to improve treatment methods.
暂无数据